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/]-GLUCURONIDASE is a hydrolytic enzyme which splits /I-glucuronic acid from
a large number of natural and synthetic 8-glucosiduronic acids. The enzyme is
widely distributed in human tissues and body fluids and has measurable activity
in blood serum and urine. Increased excretion of /8-glucuronidase has been
detected in the urine of some patients with malignant lesions (Boyland, Gasson
and Williams, 1957); cases of carcinoma of the larynx, bronchus, oesophagus,
prostate and testis showed the largest increases. The excretion of the enzyme
has been investigated most fully, however, in patients with bladder carcinoma,
where increased values have been found (Boyland, Wallace and Williams, 1955;
Lewis and Plaice, 1960; Melicow, Uson and Lipton, 1961 ; Haije and van der
Werf-Messing, 1962; Kerr, Barkin, D'Aloisio and Menczyk, 1963). Although
the urinary enzyme has been found to be increased in a wide variety of malignant
lesions, there has been little evidence that the malignant lesion itselfis the primary
source of this increase. Kerr et al. (1963) have shown that surgical removal of
bladder tumours resulted in a fall in urinary ,-glucuronidase from previously
high values to normal, and Haije and van der Werf-Messing (1962) found raised
values in cases of active bladder carcinoma but did not find elevated values in a
group ofpatients who, after radiotherapy, showed no evidence ofactive tumour at
follow-up.
It is of interest to know if other malignant lesions outwith the urinary tract
may contribute directly to increased ,8-glucuronidase in the urine. Moreover, it
is possible that increases might arise from a systemic reaction to the carcinoma,
as the urinary activity can be raised during systemic reactions such as pyrexia
(Boyland and Williams, 1956). There is also doubt whether the enzyme in the
urine is derived from renal or post-renal sources. Kerr et al. (1963) regarded it as
arising primarily from the ureters and bladder wall, but recently Fripp (1965)
has suggested that the greater part derives from glomerular filtration and active
secretion by the renal tubule cells.
In the present study, the excretion of/-glucuronidase in the urine of patients
with carcinoma of the cervix uteri receiving radiotherapy was investigated.
Evidence was obtained that the cervical lesion was presumably the primary
source of increased f8-glucuronidase in the urine of these patients, and that radia-
tion of the lesion resulted in liberation of the enzyme from the tissue.
MATERIAL AND METHODS
Patients with cancer of the cervix uteri, about to undergo a full course of
radiotherapy, were selected for this study. All subjects could readily co-operate
in the collection of specimens, were not incontinent of urine, showed no signs ofRADIOTHERAPY AND /-GLUCURONIDASE LEVELS
urinary infection, and had good renal function at the time of presentation as
measured by urea and creatinine clearance. They received total radiation doses
ranging from 5000-8500 rads. These were given in part as local radium inserted
for periods of 48-100 hours usually as two insertions, followed by a course of
supervoltage therapy from the A.E.I. Linear Accelerator administered over a
3-5 week period.
Twenty-four hour collections of urine were taken periodically, using 10 ml.
of chloroform as preservative. Two were collected before commencement of
treatment, one during each period ofradium insertion, one immediately following
each insertion, and 2-3 times per week during the course of supervoltage therapy.
Blood samples were also taken on days corresponding to the urine collections.
In 5 of the 9 patients in this series a biopsy of the malignant cervix was ob-
tained just before insertion ofthe first radium implant. After removal, the tissue
was placed in ice-cold 0-25 M-sucrose, cleansed of blood clots and exudate, dried
and stored at -20° C. It was later homogenised in 0 25 M-sucrose and the super-
natant obtained by centrifuging at 35,000 g for 60 minutes.
Estimation offi-glucuronidase in urine, serum and tissue supernatant
The pH of the urine was recorded, the volume accurately measured, and an
aliquot ofthe well-mixed specimen was centrifuged at 2000 g for 10 minutes. The
clear supernatant urine was stored at 40 C. unti lanalysis. The activity of /J-
glucuronidase in urine was measured by the method described by Melicow et al.
(1961). A unit of enzyme activity is defined as that amount of enzyme which
liberates 1 ,tg. phenolphthalein/hour at 370 C. under the test conditions. Urine
,J-glucuronidase activity is expressed as units/ml. urine or units excreted/24
hours. TUrinary creatinine was also measured by the method of Folin (1914).
The activity ofthe enzyme inblood serum andtissue supernatant was measured
by slight modification of the method of Talalay, Fishman and Huggins (1946).
0.1 ml. of test material was added to 0-8 ml. of 01 m-acetate buffer, pH 4 5, and
0.1 ml. of 0*05 m-phenolphthalein mono-fl-glucuronic acid substrate. The mix-
ture was incubated for 24 hours (serum), or periods of 1-4 hours (supernatant).
Four ml. of 0-4 M-glycine buffer, pH 10-4, was then added, the tube centrifuged
at 2000 g for 5 minutes, and the optical density of the clear supernatant read
against a blank at 550 m,u. Standards of pure phenolphthalein were used to
construct a calibration curve. The enzyme unit was the same as that defined for
urine. The serum activity was expressed as units/100 ml. The protein content
of the tissue supernatant was measured by the method of Lowry, Rosebrough,
Farr and Randall (1951), and enzyme activity expressed as units/mg. protein.
RESULTS
A normal range for urine f8-glucuronidase was obtained by taking 24 hour
urine collections from 20 healthy subjects aged 19-67 years. These gave a mean
excretion of 1520 units/24 hours, S.D. 410, with an observed range of 950-2450,
and a mean urine enzyme activity of 1-29 units/ml., S.D. 0-36, with an observed
range of 0-74-1-93 units/ml. A normal range for serum ,/-glucuronidase from 30
healthy subjects aged 19-60 was found to be 200-1000 units/100 ml.
In order to group the results on all 9 patients together for statistical analysis,
the scheme ofradiotherapy foreach patient was dividedinto phases, andtheresults
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calculated from urine collections and blood specimens taken during each phase.
These were as follows:
1. Pre-treatment comprising 2 consecutive 24 hour urine collections, with 2
blood specimens, taken before treatment commenced.
2. Radium treatment five of the patients had 2 separate insertions of radium.
Consequently, each had a total of 4 urine collections and blood specimens taken
during radium treatment-2 with radium in situ and 2 following withdrawal.
The remaining 4 patients had only one insertion and, therefore, only a total of 2
urine and blood specimens per patient.
3. Supervoltage therapy this was divided into 3 separate weekly periods on all
the patients. Some had a 4th or 5th week of therapy, but data from urine
collections and blood specimens taken after the 3rd week have only been presented
for 2 patients where they were of special significance.
The mean /-glucuronidase value for each patient at each phase of therapy was
calculated for blood and urine from the results of all specimens taken during each
phase. In the figures presenting data on the individual patients, each point will
be a mean result from 2 to 4 separate specimens. In the tables of statistical data
on the 9 patients as a group, the mean ± S.E. for each phase of treatment was
calculated from the mean /-glucuronidase value of each individual patient.
The collective data on the 9 patients are shown in Table I, with the results
TABLE I. Activity of /3-Glucuronidase in Urine during Radiotherapy
Urine fl-glucuronidase
Daily excretion Activity
units/24 hours units/ml. urine
Mean ± S.E. P Mean t S.E. P
Pre-treatment . 2270± 405 1 66±0 25
Radium treatment 3577± 685 <0*01 2*71±0 45 <0*01
Supervoltage
Week1. . . 4310±1023 <0*02 2-84±+ 0 51 < 0 05
Week 2 . 3360±1133 n.s. 2-33±0-48 n.s.
Week 3 . . 3380±1436 n.s. 1-86±0-38 n.s.
Number of patients 9
S.E. = standard error of the mean; n.s. = not significant.
P values were obtained by applying the Student t test to the difference between the mean for
each treatment and the pro-treatment value.
expressed as 24 hour excretion of enzyme and as units/ml. urine. They were also
calculated as units/mg. urinary creatinine but this did not produce significant
variation from those presented and so have not been included. As can be seen
from the S.E. of the means during each treatment, there was a large patient
variation in enzyme output before and after radiotherapy. In spite of this, it
was shown statistically that an increase in urinary enzyme occurred during and
following radium therapy. The concomitant increase in enzyme activity in
units/ml. indicated a true increase in enzyme output and not simply increased
urine volume.
There was, however, variation between the patients in the group. This is
shown in Fig. 1. The cases were divided into those with an abnormally high
pre-treatment 8-glucuronidase excretion and those with normal values. It
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FIG. 1. Urinary excretion of ,B-glucuronidase during radiotherapy of carcinoma of cervix uteri.
should be noted that the largest increases in enzyme excretion occurred in those
patients with high pre-treatment excretion. The very large increases seen in
Case C.2 were accompanied by a diuresis occurring in the 2nd and 3rd weeks of
supervoltage therapy; there was, however, an increase also in enzyme activity
as units/ml. in the 3rd week. Collections taken on this patient for a further 2
weeks of radiotherapy showed a fall in enzyme excretion over this period to
approximately 7000 units/24 hours.
Of the 5 patients with normal pre-treatment /-glucuronidase excretion,
2 Cases C.5 and C.6-showed a definite increase in enzyme excretion occurring
over the same period as the 4 high-excretion cases. Case C.7 appeared also to
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show a slight increase, although not to values outside the normal range. The
remaining 2 cases showed no response to radiation and produced remarkably
constant urine values over the whole course of therapy.
There appeared to be only a slight correlation between the degree ofmalignancy
of the tumour and the 3-glucuronidase response. The 4 patients in the high-
excretion group all showed highly malignant features on histological examination,
with poor differentiation and a high mitotic rate. However, in the low-excretion
group Case C.8 which produced no response in urinary ,-glucuronidase was classed
similarly to these patients, while Cases C.5 and C.6, which showed the largest
response in this group, had well-differentiated features with a low mitotic rate.
The pattern of,-glucuronidase excretion was also not related to the total radiation
dose administered.
Serum f-glucuronidase results from specimens taken at times corresponding
to urine collections are shown in Table II. All except one case showed an increase
TABLE II.-Activity of Serum /f-Glucuronidase during Radiotherapy
Serum fl-glucuronidase
(units/100 ml.)
Mean ± S.E. P
Pre-treatment . 646t58
Radium treatment . . 794±43 <0.01
Supervoltage treatment
Week . 662473 n.s.
Week 2 . 701± 84 n.s.
Week 3 . . 676 85 n.s.
in serum enzyme activity during radium therapy. Thereafter, results were
unpredictable. This is shown in Fig. 2 where it can be seen that 3 cases showed
further increases to abnormally high values during supervoltage therapy, 4 showed
subsequent decreases, and 2 showed no obvious change.
It is clear that cases which produced increased excretion of /I-glucuronidase
during radium treatment also showed increased enzyme activity in the serum.
Case C.8, which did not produce an increase in urine activity, also failed to show a
rise in serum 8-glucuronidase. There did not appear to be a connection between
the urine and serum results over the period of supervoltage therapy, except in 2
cases. These are shown in Fig. 3 and appear to exhibit a reciprocal relationship
between serum and urine 8-glucuronidase. Both cases showed a coincident
increase in urine and serum enzyme during radium therapy. Case C.5 then
produced a dramatic fall in urine enzyme output to subnormal values of 200-400
units/24 hours during the 4th and 5th weeks of deep X-ray therapy, which was
accompanied by a rise in serum enzyme activity to abnormal values.
Biopsy material for the analysis of tissue ,-glucuronidase activity was ob-
tained in Cases C.1, 2, 3, 5, and 8. Of the cases with a high initial excretion of
the enzyme, C.2 and C.3 had a very high tissue activity 44 and 46 units/mg.
protein (12 specimens of non-cancerous cervical tissue gave a range of 0.6-8
units/mg. protein). In the cases with normal pre-treatment excretion, C.5 had
a moderate tissue activity-17 units/mg. protein-and showed an increase in
urinary /8-glucuronidase following radiation, although not so marked as Cases
C.2 and C.3; Case C.8 showed no change in urine enzyme and had low tissue
activity-7 units/mg. protein. From these results, there would appear to be a
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relationship between excretion of the enzyme in the urine following irradiation of
the tissue by radium insertion and the ,3-glucuronidase activity of the carcinoma
tissue. However, Case C.1 does not appear to uphold this hypothesis. This case
had a high initial excretion of f8-glucuronidase which increased following radium
therapy, but the corresponding tissue specimen showed only a low enzyme activity
of 6 units/mg. protein. It is possible that in this case the biopsy obtained was
not truly representative of the tumour. The patient was found to have a highly
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FIG. 2.-Serum fl-glucuronidase during radiotherapy. Cases are grouped according to the
pattemn of enzyme response during supervoltage therapy.
malignant lesion, whereas the tissue /?-glucuronidase activity was much lower
than normally encountered in this type, the activity being in the non-cancerous
range quoted above.
Fig. 4 shows data on 2 cases, one with carcinoma of the oesophagus and one
with carcinoma of the bronchus, who had a high pre-treatment excretion of
urinary /-glucuronidase and showed a pronounced increase in enzyme output
during supervoltage therapy. The data were derived in the same way as the
cervical carcinoma cases. These were only 2 cases in a group of 8 patients with
carcinoma in the thoracic region who had a high initial excretion of /?-glucuro-
nidase. They have been included to illustrate that an increase in ,3-glucuronidase
excretion can occur in patients receiving radiation distant from the renal tract.
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FIG. 3.-Reciprocal relationship of serum and urinary fl-glucuronidase in 2 patients
during radiotherapy.
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FIG. 4.-f,-Glucuronidase excretion in 2 patients with thoracic carcinoma and high
pre-treatment enzyme output receiving radiotherapy.
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DISCUSSION
There are no similar studies on the urinary excretion of f8-glucuronidase
following radiation with which to compare the present work. Although increased
excretion of the enzyme has been observed in patients with various malignant
lesions, little evidence has accrued that the malignant lesion is the major
contributor.
Results obtained in the present study on patients with cervical carcinoma
suggest that the lesion in the cervix uteri is the source of increased fl-glucuro-
nidase observed in the urine of some of these patients. Insertion of radium was
followed by increased excretion of fl-glucuronidase in 7 of the 9 patients, which
lasted for approximately 2-3 weeks and then fell back to, and often below, the
pre-radiation values. Furthermore, the patients with an abnormal excretion of
,8-glucuronidase before radiotherapy, produced the most pronounced increases.
The rises in ,3-glucuronidase excretion were accompanied by increased serum
,8-glucuronidase activity. This suggests that the enzyme is liberated from the
cancer tissue, enters the circulation, and is then cleared by the kidneys. Kerr
et al. (1963) have suggested that a great proportion of the 8-glucuronidase in
normal urine is derived from the urethra and bladder mucosa. On the other
hand, studies by Fripp (1965) have suggested that the largest proportion has
come from glomerular filtration of the enzyme and active secretion by the tubule
cells. The results ofthe present work are best explained by renal clearance ofthe
enzyme. The reciprocal relationship between serum and urine activity which
occurred in 2 cases could arise from inadequate clearance causing an increase in
circulating enzyme in the blood.
It is not unreasonable to separate the cases with a high initial 24 hour excretion
of enzyme from those with a normal value, as it is feasible that the enzyme excre-
tion in the two groups will vary in different ways during radiation, e.g. it might
have been possible to detect a fall in enzyme in the high-excretion group which
would not have shown in a convincing manner in the low-excretion cases. This
reasoning is independent of whether the urine enzyme is derived from the malig-
nant tissue directly or is due to a systemic reaction. Indeed, the latter possibi-
lity could be advanced as an explanation ofthe observed results. The high initial
enzyme excretion in 4 patients could be a reflection ofa labile or more pronounced
systemic reaction, and the comparatively larger increases in enzyme output in
these cases consequent to radiation could be viewed as a further manifestation of
this reaction following further trauma to the patient. However, it would be
extremely difficult to investigate this possibility in a control series of patients, i.e.
those receiving radiation but without a malignant lesion. There is a strong
suggestion, when comparing the tissue and urine results in 4 of the 5 patients
in whom such an assessment was possible, that there is a connection between
the ,3-glucuronidase activity of the malignant lesion and the urinary excretion
of the enzyme following radiation of the lesion. This militates against these
results being due to non-specific reactions to radiation.
Consideration must be given to the possibility that these results could have
arisen from secondary damage to the kidneys due to their proximity to the field of
radiation. Radiation nephritis has been described in patients receiving lower
abdominal radiotherapy, although this only manifests itself at a later date, on
average 8 months after therapy (Kunkler, Farr and Luxton, 1952). There was
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no clinical or biochemical evidence to suggest that the transient increase in /J-
glucuronidase excretion following radium treatment was due to renal impairment.
Measurement ofurea and creatinine clearance at the conclusion oftherapy showed
no change in renal function. Moreover, increases in urinary enzyme following
radiation were observed in patients receiving radiotherapy at sites distant from
the urinary tract (Fig. 4).
Takiguchi (1963) has stated that,8-glucuronidase in serum of patients with
cancer of cervix uteri receiving radiotherapy may be related to the clinical and
radiation response of the patient. The present group is too small, and has been
followed up for too short a period to permit an assessment of the prognostic value
of increased serum and urinary /-glucuronidase found after radiation.
SUMMARY
Insertion of radium and subsequent deep X-ray therapy in patients with
carcinoma of the cervix uteri caused a significant increase in excretion of /?-
glucuronidase in the urine. This was most pronounced in patients who had an
abnormally high excretion of the enzyme before radiotherapy. Increased serum
,8-glucuronidase activity was seen during radium treatment in all but one of the
patients. The /?-glucuronidase excretion appeared to be correlated with the
activity of the enzyme in the irradiated tumour. It is suggested that the
tumour is the direct source ofincreased urinary enzyme in these patients, and that
during radiotherapy the enzyme is liberated from the tissue and is cleared via the
kidneys.
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